Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment

Loading news article.

Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment | WAPE

Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment

Article summary

Related companies

Comments —